Photo from wikipedia
In this open‐label, international phase 2 study, the authors assessed the efficacy and safety of olmutinib in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) who had… Click to show full abstract
In this open‐label, international phase 2 study, the authors assessed the efficacy and safety of olmutinib in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) who had a confirmed T790M mutation and disease progression on previous epidermal growth factor receptor‐tyrosine kinase inhibitor therapy.
Keywords:
lung cancer;
cell lung;
non small;
cancer;
phase study;
small cell
Journal Title: Cancer
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!